Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Inlyta | Axitinib | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Proleukin | Aldesleukin (IL-2) | In-transit Melanoma | Reimburse | Complete | ||
| Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
| Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete | ||
| Velcade | Bortezomib | Multiple Myeloma | Reimburse | Complete | ||
| Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Votrient | Pazopanib hydrochloride | Metastatic Renal Cell Carcinoma | Reimburse | Complete | ||
| Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Reimburse | Complete | ||
| N/A | abiraterone, prednisone, docetaxel | Metastatic castration sensitive prostate cancer (mCSPC) | Reimburse | Complete | ||
| Keytruda | Pembrolizumab | classical Hodgkin Lymphoma (cHL) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 17, 2024